FDA clears Inqovi plus venetoclax for newly diagnosed AML: full analysis

The FDA on May 13, 2026 approved Inqovi plus venetoclax for adults with newly diagnosed acute myeloid leukemia who are either 75 or older or not candidates for intensive induction chemotherapy, giving this AML population the first fully oral frontline combination regimen cleared in the U.S. Taiho Oncology had previously framed the application as a potential all-oral alternative to existing treatment approaches, and the approval now formalizes that option. (fda.gov)

This approval follows Taiho’s July 9, 2025 announcement that the FDA had accepted its supplemental NDA for the regimen, with a PDUFA target date of February 25, 2026. At that point, the company said the filing was supported by the Phase 2b ASCERTAIN-V study in 101 adults with newly diagnosed AML who were ineligible for intensive induction chemotherapy. Inqovi was already marketed in the U.S. for myelodysplastic syndromes and chronic myelomonocytic leukemia, so the AML decision extends the drug into a new frontline setting. (taihooncology.com)

According to the FDA’s approval summary, efficacy was evaluated in Study ASTX727-07, also identified in company materials as ASCERTAIN-V. In the 101-patient, single-arm, open-label trial, 42 patients achieved complete remission, for a CR rate of 41.6% with a 95% confidence interval of 31.9 to 51.8. Median time to complete remission was two months, and median duration of complete remission had not yet been reached at the time of the FDA summary. The recommended regimen is one Inqovi tablet, containing 35 mg decitabine and 100 mg cedazuridine, once daily on days 1 through 5 of each 28-day cycle, together with venetoclax, until progression or unacceptable toxicity. FDA highlighted myelosuppression and embryo-fetal toxicity among the warnings and precautions. (fda.gov)

Additional context from conference and secondary coverage suggests the approval builds on growing interest in oral hypomethylating-agent-based AML regimens. Coverage of ASCERTAIN-V data presented in 2025 described the regimen as potentially practice-changing for patients who are older or unfit for induction chemotherapy, with reports pointing to encouraging remission and survival outcomes. A prior phase 2 study published in The Lancet Haematology had also supported the feasibility of oral decitabine-cedazuridine plus venetoclax in older or unfit AML populations, though that earlier study was smaller and not itself the basis of this approval. (cancernetwork.com)

Industry reaction has centered on convenience and access. Taiho said in its earlier regulatory announcement that, if approved, the regimen would offer the first all-oral alternative for this AML population. Trade coverage following the decision echoed that point, emphasizing the possibility of reducing treatment burden tied to hospital- or infusion-based care. That convenience argument may resonate especially in older AML populations, where repeated clinic visits can be a major barrier, although clinicians will still need to manage cytopenias, monitoring, dose adjustments, and supportive care carefully. (taihooncology.com)

Why it matters: For veterinary professionals, this is not a veterinary regulatory event, but it is a useful marker of where oncology care is heading more broadly: toward oral regimens, outpatient management, and treatment models designed around patient and caregiver burden as well as efficacy. That trend matters in translational medicine, comparative oncology, and the wider life sciences ecosystem that many veterinary professionals track. It also reflects how regulators are increasingly willing to evaluate combination regimens that improve practicality for older, medically fragile patients, not just raw response metrics. That said, the approval rests on a single-arm study, so long-term comparative effectiveness, adherence in real-world use, and safety management outside trial settings will remain important questions. (fda.gov)

Another notable element is the regulatory pathway. FDA said the review was conducted under Project Orbis, with collaboration from Health Canada, signaling the continuing use of international review frameworks in oncology. The product also received orphan drug designation for this indication. Those details suggest the agency continues to prioritize hematologic malignancies where unmet need remains high, especially in populations poorly served by intensive chemotherapy. (fda.gov)

What to watch: The next key developments are the posting of the updated full prescribing information in Drugs@FDA, early clinician uptake in community practice, payer coverage, and follow-up data that clarify remission durability, survival, and how this all-oral regimen compares in day-to-day use with established azacitidine-venetoclax approaches. (fda.gov)